nodes	percent_of_prediction	percent_of_DWPC	metapath
Midodrine—CYP2D6—Niacin—atherosclerosis	0.154	0.3	CbGbCtD
Midodrine—CYP2D6—Simvastatin—atherosclerosis	0.121	0.237	CbGbCtD
Midodrine—CYP2D6—Pravastatin—atherosclerosis	0.119	0.232	CbGbCtD
Midodrine—CYP2D6—Lovastatin—atherosclerosis	0.119	0.232	CbGbCtD
Midodrine—Hair disorder—Pravastatin—atherosclerosis	0.0204	0.0528	CcSEcCtD
Midodrine—Drug interaction—Rosuvastatin—atherosclerosis	0.00695	0.018	CcSEcCtD
Midodrine—Heartburn—Niacin—atherosclerosis	0.00682	0.0177	CcSEcCtD
Midodrine—Hepatic enzyme increased—Rosuvastatin—atherosclerosis	0.00682	0.0177	CcSEcCtD
Midodrine—Heartburn—Pravastatin—atherosclerosis	0.00671	0.0174	CcSEcCtD
Midodrine—Drug interaction—Ezetimibe—atherosclerosis	0.00578	0.015	CcSEcCtD
Midodrine—Drug interaction—Simvastatin—atherosclerosis	0.00551	0.0143	CcSEcCtD
Midodrine—Sleep disorder—Rosuvastatin—atherosclerosis	0.00541	0.014	CcSEcCtD
Midodrine—Drug interaction—Pravastatin—atherosclerosis	0.00498	0.0129	CcSEcCtD
Midodrine—Hepatic function abnormal—Lovastatin—atherosclerosis	0.00454	0.0118	CcSEcCtD
Midodrine—Cramps of lower extremities—Niacin—atherosclerosis	0.00431	0.0112	CcSEcCtD
Midodrine—Sleep disorder—Simvastatin—atherosclerosis	0.00429	0.0111	CcSEcCtD
Midodrine—Hepatic function abnormal—Simvastatin—atherosclerosis	0.00424	0.011	CcSEcCtD
Midodrine—Hepatic function abnormal—Niacin—atherosclerosis	0.0039	0.0101	CcSEcCtD
Midodrine—Sleep disorder—Pravastatin—atherosclerosis	0.00387	0.0101	CcSEcCtD
Midodrine—Hepatic function abnormal—Pravastatin—atherosclerosis	0.00384	0.00996	CcSEcCtD
Midodrine—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00341	0.00886	CcSEcCtD
Midodrine—Abdominal discomfort—Lovastatin—atherosclerosis	0.00329	0.00853	CcSEcCtD
Midodrine—Urinary retention—Niacin—atherosclerosis	0.00324	0.00841	CcSEcCtD
Midodrine—Melatonin—MPO—atherosclerosis	0.00324	0.571	CrCbGaD
Midodrine—Dry skin—Niacin—atherosclerosis	0.00312	0.00811	CcSEcCtD
Midodrine—Dry skin—Pravastatin—atherosclerosis	0.00307	0.00798	CcSEcCtD
Midodrine—Abdominal discomfort—Simvastatin—atherosclerosis	0.00307	0.00798	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.00303	0.00787	CcSEcCtD
Midodrine—Mental disorder—Rosuvastatin—atherosclerosis	0.00284	0.00736	CcSEcCtD
Midodrine—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00284	0.00736	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.00283	0.00736	CcSEcCtD
Midodrine—Flatulence—Rosuvastatin—atherosclerosis	0.00278	0.00721	CcSEcCtD
Midodrine—Dysuria—Pravastatin—atherosclerosis	0.00271	0.00704	CcSEcCtD
Midodrine—Erythema multiforme—Lovastatin—atherosclerosis	0.00259	0.00674	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.00256	0.00665	CcSEcCtD
Midodrine—Stomatitis—Niacin—atherosclerosis	0.00256	0.00664	CcSEcCtD
Midodrine—Flushing—Lovastatin—atherosclerosis	0.00255	0.00661	CcSEcCtD
Midodrine—Erythema multiforme—Ezetimibe—atherosclerosis	0.00254	0.00661	CcSEcCtD
Midodrine—Flushing—Ezetimibe—atherosclerosis	0.0025	0.00648	CcSEcCtD
Midodrine—Chills—Lovastatin—atherosclerosis	0.00246	0.00639	CcSEcCtD
Midodrine—Angiopathy—Ezetimibe—atherosclerosis	0.00244	0.00634	CcSEcCtD
Midodrine—Melatonin—ESR1—atherosclerosis	0.00243	0.429	CrCbGaD
Midodrine—Erythema multiforme—Simvastatin—atherosclerosis	0.00243	0.0063	CcSEcCtD
Midodrine—Flushing—Simvastatin—atherosclerosis	0.00238	0.00618	CcSEcCtD
Midodrine—Mental disorder—Ezetimibe—atherosclerosis	0.00236	0.00612	CcSEcCtD
Midodrine—Flatulence—Lovastatin—atherosclerosis	0.00235	0.00611	CcSEcCtD
Midodrine—Confusional state—Rosuvastatin—atherosclerosis	0.00232	0.00602	CcSEcCtD
Midodrine—Back pain—Lovastatin—atherosclerosis	0.00231	0.006	CcSEcCtD
Midodrine—Flatulence—Ezetimibe—atherosclerosis	0.00231	0.00599	CcSEcCtD
Midodrine—Chills—Simvastatin—atherosclerosis	0.0023	0.00598	CcSEcCtD
Midodrine—Muscle spasms—Lovastatin—atherosclerosis	0.0023	0.00596	CcSEcCtD
Midodrine—Back pain—Ezetimibe—atherosclerosis	0.00227	0.00588	CcSEcCtD
Midodrine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00226	0.00586	CcSEcCtD
Midodrine—Muscle spasms—Ezetimibe—atherosclerosis	0.00225	0.00585	CcSEcCtD
Midodrine—Mental disorder—Simvastatin—atherosclerosis	0.00225	0.00584	CcSEcCtD
Midodrine—Flatulence—Simvastatin—atherosclerosis	0.0022	0.00572	CcSEcCtD
Midodrine—Erythema multiforme—Pravastatin—atherosclerosis	0.00219	0.0057	CcSEcCtD
Midodrine—Flushing—Niacin—atherosclerosis	0.00219	0.00568	CcSEcCtD
Midodrine—Cardiac disorder—Pravastatin—atherosclerosis	0.00215	0.00559	CcSEcCtD
Midodrine—Flushing—Pravastatin—atherosclerosis	0.00215	0.00559	CcSEcCtD
Midodrine—Muscle spasms—Simvastatin—atherosclerosis	0.00215	0.00558	CcSEcCtD
Midodrine—Angiopathy—Niacin—atherosclerosis	0.00214	0.00555	CcSEcCtD
Midodrine—Chills—Niacin—atherosclerosis	0.00211	0.00549	CcSEcCtD
Midodrine—Chills—Pravastatin—atherosclerosis	0.00208	0.00541	CcSEcCtD
Midodrine—Insomnia—Rosuvastatin—atherosclerosis	0.00208	0.0054	CcSEcCtD
Midodrine—Paraesthesia—Rosuvastatin—atherosclerosis	0.00207	0.00536	CcSEcCtD
Midodrine—Anxiety—Lovastatin—atherosclerosis	0.00203	0.00526	CcSEcCtD
Midodrine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00202	0.00526	CcSEcCtD
Midodrine—Hypertension—Ezetimibe—atherosclerosis	0.00202	0.00525	CcSEcCtD
Midodrine—Flatulence—Niacin—atherosclerosis	0.00202	0.00525	CcSEcCtD
Midodrine—Tension—Niacin—atherosclerosis	0.00201	0.00523	CcSEcCtD
Midodrine—Nervousness—Niacin—atherosclerosis	0.00199	0.00517	CcSEcCtD
Midodrine—Flatulence—Pravastatin—atherosclerosis	0.00199	0.00517	CcSEcCtD
Midodrine—Dry mouth—Lovastatin—atherosclerosis	0.00199	0.00516	CcSEcCtD
Midodrine—Tension—Pravastatin—atherosclerosis	0.00198	0.00515	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00198	0.00514	CcSEcCtD
Midodrine—Muscle spasms—Niacin—atherosclerosis	0.00197	0.00512	CcSEcCtD
Midodrine—Pain—Rosuvastatin—atherosclerosis	0.00197	0.00511	CcSEcCtD
Midodrine—Confusional state—Lovastatin—atherosclerosis	0.00197	0.0051	CcSEcCtD
Midodrine—Nervousness—Pravastatin—atherosclerosis	0.00196	0.00509	CcSEcCtD
Midodrine—Dry mouth—Ezetimibe—atherosclerosis	0.00195	0.00506	CcSEcCtD
Midodrine—Muscle spasms—Pravastatin—atherosclerosis	0.00194	0.00504	CcSEcCtD
Midodrine—Confusional state—Ezetimibe—atherosclerosis	0.00193	0.00501	CcSEcCtD
Midodrine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.0019	0.00492	CcSEcCtD
Midodrine—Anxiety—Simvastatin—atherosclerosis	0.0019	0.00492	CcSEcCtD
Midodrine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00188	0.00488	CcSEcCtD
Midodrine—Nervous system disorder—Ezetimibe—atherosclerosis	0.00188	0.00487	CcSEcCtD
Midodrine—Skin disorder—Ezetimibe—atherosclerosis	0.00186	0.00482	CcSEcCtD
Midodrine—Confusional state—Simvastatin—atherosclerosis	0.00184	0.00477	CcSEcCtD
Midodrine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00182	0.00472	CcSEcCtD
Midodrine—Insomnia—Lovastatin—atherosclerosis	0.00176	0.00458	CcSEcCtD
Midodrine—Paraesthesia—Lovastatin—atherosclerosis	0.00175	0.00454	CcSEcCtD
Midodrine—Hypertension—Pravastatin—atherosclerosis	0.00174	0.00453	CcSEcCtD
Midodrine—Dyspnoea—Lovastatin—atherosclerosis	0.00174	0.00451	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00173	0.0045	CcSEcCtD
Midodrine—Insomnia—Ezetimibe—atherosclerosis	0.00173	0.00449	CcSEcCtD
Midodrine—Paraesthesia—Ezetimibe—atherosclerosis	0.00172	0.00446	CcSEcCtD
Midodrine—Dyspepsia—Lovastatin—atherosclerosis	0.00172	0.00446	CcSEcCtD
Midodrine—Anxiety—Pravastatin—atherosclerosis	0.00171	0.00445	CcSEcCtD
Midodrine—Dry mouth—Niacin—atherosclerosis	0.00171	0.00443	CcSEcCtD
Midodrine—Dyspnoea—Ezetimibe—atherosclerosis	0.0017	0.00443	CcSEcCtD
Midodrine—Dyspepsia—Ezetimibe—atherosclerosis	0.00168	0.00437	CcSEcCtD
Midodrine—Pain—Lovastatin—atherosclerosis	0.00167	0.00433	CcSEcCtD
Midodrine—Confusional state—Pravastatin—atherosclerosis	0.00166	0.00432	CcSEcCtD
Midodrine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00165	0.00429	CcSEcCtD
Midodrine—Asthenia—Rosuvastatin—atherosclerosis	0.00165	0.00428	CcSEcCtD
Midodrine—Insomnia—Simvastatin—atherosclerosis	0.00165	0.00428	CcSEcCtD
Midodrine—Paraesthesia—Simvastatin—atherosclerosis	0.00164	0.00425	CcSEcCtD
Midodrine—Pain—Ezetimibe—atherosclerosis	0.00164	0.00425	CcSEcCtD
Midodrine—Tachycardia—Niacin—atherosclerosis	0.00163	0.00424	CcSEcCtD
Midodrine—Pruritus—Rosuvastatin—atherosclerosis	0.00163	0.00423	CcSEcCtD
Midodrine—Skin disorder—Niacin—atherosclerosis	0.00163	0.00422	CcSEcCtD
Midodrine—Dyspnoea—Simvastatin—atherosclerosis	0.00163	0.00422	CcSEcCtD
Midodrine—Feeling abnormal—Lovastatin—atherosclerosis	0.00161	0.00417	CcSEcCtD
Midodrine—Dyspepsia—Simvastatin—atherosclerosis	0.00161	0.00417	CcSEcCtD
Midodrine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00159	0.00414	CcSEcCtD
Midodrine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00158	0.00409	CcSEcCtD
Midodrine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00157	0.00409	CcSEcCtD
Midodrine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00156	0.00406	CcSEcCtD
Midodrine—Pain—Simvastatin—atherosclerosis	0.00156	0.00405	CcSEcCtD
Midodrine—Abdominal pain—Lovastatin—atherosclerosis	0.00154	0.004	CcSEcCtD
Midodrine—Dizziness—Rosuvastatin—atherosclerosis	0.00152	0.00395	CcSEcCtD
Midodrine—Insomnia—Niacin—atherosclerosis	0.00151	0.00393	CcSEcCtD
Midodrine—Abdominal pain—Ezetimibe—atherosclerosis	0.00151	0.00392	CcSEcCtD
Midodrine—Paraesthesia—Niacin—atherosclerosis	0.0015	0.0039	CcSEcCtD
Midodrine—Feeling abnormal—Simvastatin—atherosclerosis	0.0015	0.0039	CcSEcCtD
Midodrine—Dyspnoea—Niacin—atherosclerosis	0.00149	0.00388	CcSEcCtD
Midodrine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00149	0.00387	CcSEcCtD
Midodrine—Insomnia—Pravastatin—atherosclerosis	0.00149	0.00387	CcSEcCtD
Midodrine—Somnolence—Niacin—atherosclerosis	0.00149	0.00386	CcSEcCtD
Midodrine—Paraesthesia—Pravastatin—atherosclerosis	0.00148	0.00384	CcSEcCtD
Midodrine—Dyspepsia—Niacin—atherosclerosis	0.00147	0.00383	CcSEcCtD
Midodrine—Dyspnoea—Pravastatin—atherosclerosis	0.00147	0.00382	CcSEcCtD
Midodrine—Dyspepsia—Pravastatin—atherosclerosis	0.00145	0.00377	CcSEcCtD
Midodrine—Rash—Rosuvastatin—atherosclerosis	0.00145	0.00377	CcSEcCtD
Midodrine—Dermatitis—Rosuvastatin—atherosclerosis	0.00145	0.00376	CcSEcCtD
Midodrine—Gastrointestinal disorder—Niacin—atherosclerosis	0.00145	0.00375	CcSEcCtD
Midodrine—Abdominal pain—Simvastatin—atherosclerosis	0.00144	0.00374	CcSEcCtD
Midodrine—Headache—Rosuvastatin—atherosclerosis	0.00144	0.00374	CcSEcCtD
Midodrine—Pain—Niacin—atherosclerosis	0.00143	0.00372	CcSEcCtD
Midodrine—Pain—Pravastatin—atherosclerosis	0.00141	0.00366	CcSEcCtD
Midodrine—Asthenia—Lovastatin—atherosclerosis	0.0014	0.00363	CcSEcCtD
Midodrine—Pruritus—Lovastatin—atherosclerosis	0.00138	0.00358	CcSEcCtD
Midodrine—Asthenia—Ezetimibe—atherosclerosis	0.00137	0.00356	CcSEcCtD
Midodrine—Gastrointestinal pain—Niacin—atherosclerosis	0.00137	0.00355	CcSEcCtD
Midodrine—Nausea—Rosuvastatin—atherosclerosis	0.00137	0.00355	CcSEcCtD
Midodrine—Feeling abnormal—Pravastatin—atherosclerosis	0.00136	0.00353	CcSEcCtD
Midodrine—Pruritus—Ezetimibe—atherosclerosis	0.00135	0.00351	CcSEcCtD
Midodrine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00135	0.0035	CcSEcCtD
Midodrine—Abdominal pain—Niacin—atherosclerosis	0.00132	0.00344	CcSEcCtD
Midodrine—Asthenia—Simvastatin—atherosclerosis	0.00131	0.0034	CcSEcCtD
Midodrine—Abdominal pain—Pravastatin—atherosclerosis	0.0013	0.00338	CcSEcCtD
Midodrine—Pruritus—Simvastatin—atherosclerosis	0.00129	0.00335	CcSEcCtD
Midodrine—Dizziness—Lovastatin—atherosclerosis	0.00129	0.00335	CcSEcCtD
Midodrine—Dizziness—Ezetimibe—atherosclerosis	0.00126	0.00328	CcSEcCtD
Midodrine—Rash—Lovastatin—atherosclerosis	0.00123	0.00319	CcSEcCtD
Midodrine—Dermatitis—Lovastatin—atherosclerosis	0.00123	0.00319	CcSEcCtD
Midodrine—Headache—Lovastatin—atherosclerosis	0.00122	0.00317	CcSEcCtD
Midodrine—Dizziness—Simvastatin—atherosclerosis	0.00121	0.00313	CcSEcCtD
Midodrine—Rash—Ezetimibe—atherosclerosis	0.00121	0.00313	CcSEcCtD
Midodrine—Dermatitis—Ezetimibe—atherosclerosis	0.0012	0.00313	CcSEcCtD
Midodrine—Asthenia—Niacin—atherosclerosis	0.0012	0.00312	CcSEcCtD
Midodrine—Headache—Ezetimibe—atherosclerosis	0.0012	0.00311	CcSEcCtD
Midodrine—Pruritus—Niacin—atherosclerosis	0.00118	0.00308	CcSEcCtD
Midodrine—Asthenia—Pravastatin—atherosclerosis	0.00118	0.00307	CcSEcCtD
Midodrine—Pruritus—Pravastatin—atherosclerosis	0.00117	0.00303	CcSEcCtD
Midodrine—Nausea—Lovastatin—atherosclerosis	0.00116	0.00301	CcSEcCtD
Midodrine—Rash—Simvastatin—atherosclerosis	0.00115	0.00298	CcSEcCtD
Midodrine—Dermatitis—Simvastatin—atherosclerosis	0.00115	0.00298	CcSEcCtD
Midodrine—Headache—Simvastatin—atherosclerosis	0.00114	0.00297	CcSEcCtD
Midodrine—Nausea—Ezetimibe—atherosclerosis	0.00114	0.00295	CcSEcCtD
Midodrine—Dizziness—Niacin—atherosclerosis	0.00111	0.00287	CcSEcCtD
Midodrine—Dizziness—Pravastatin—atherosclerosis	0.00109	0.00283	CcSEcCtD
Midodrine—Nausea—Simvastatin—atherosclerosis	0.00108	0.00281	CcSEcCtD
Midodrine—Rash—Niacin—atherosclerosis	0.00106	0.00274	CcSEcCtD
Midodrine—Dermatitis—Niacin—atherosclerosis	0.00105	0.00274	CcSEcCtD
Midodrine—Headache—Niacin—atherosclerosis	0.00105	0.00272	CcSEcCtD
Midodrine—Rash—Pravastatin—atherosclerosis	0.00104	0.0027	CcSEcCtD
Midodrine—Dermatitis—Pravastatin—atherosclerosis	0.00104	0.0027	CcSEcCtD
Midodrine—Headache—Pravastatin—atherosclerosis	0.00103	0.00268	CcSEcCtD
Midodrine—Nausea—Niacin—atherosclerosis	0.000994	0.00258	CcSEcCtD
Midodrine—Nausea—Pravastatin—atherosclerosis	0.000979	0.00254	CcSEcCtD
Midodrine—ADRA1D—Signaling Pathways—APOC3—atherosclerosis	6.06e-05	0.000629	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—LDLR—atherosclerosis	6.02e-05	0.000625	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CX3CL1—atherosclerosis	5.99e-05	0.000622	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—AGT—atherosclerosis	5.93e-05	0.000616	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—EDN1—atherosclerosis	5.93e-05	0.000616	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APOA2—atherosclerosis	5.93e-05	0.000616	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CCL5—atherosclerosis	5.89e-05	0.000611	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCL3—atherosclerosis	5.88e-05	0.000611	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—KNG1—atherosclerosis	5.68e-05	0.00059	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CNR2—atherosclerosis	5.68e-05	0.00059	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—CXCL8—atherosclerosis	5.67e-05	0.000589	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—MMP3—atherosclerosis	5.66e-05	0.000588	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—UTS2—atherosclerosis	5.66e-05	0.000588	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	5.65e-05	0.000587	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AGTR1—atherosclerosis	5.64e-05	0.000586	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NCF1—atherosclerosis	5.63e-05	0.000585	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PRKCG—atherosclerosis	5.6e-05	0.000581	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—F2—atherosclerosis	5.48e-05	0.000569	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CX3CR1—atherosclerosis	5.42e-05	0.000563	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CASR—atherosclerosis	5.42e-05	0.000563	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ABCG1—atherosclerosis	5.4e-05	0.000561	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—AGT—atherosclerosis	5.39e-05	0.00056	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—EDN1—atherosclerosis	5.39e-05	0.000559	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CCL5—atherosclerosis	5.35e-05	0.000555	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EDNRA—atherosclerosis	5.32e-05	0.000552	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CX3CL1—atherosclerosis	5.32e-05	0.000552	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCR2—atherosclerosis	5.32e-05	0.000552	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CYBA—atherosclerosis	5.3e-05	0.00055	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—EDN1—atherosclerosis	5.27e-05	0.000547	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CG—atherosclerosis	5.25e-05	0.000545	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CCL5—atherosclerosis	5.23e-05	0.000543	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PLAT—atherosclerosis	5.18e-05	0.000538	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PARP1—atherosclerosis	5.18e-05	0.000538	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—GHRL—atherosclerosis	5.18e-05	0.000538	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PRKCG—atherosclerosis	5.08e-05	0.000528	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—FABP4—atherosclerosis	5.08e-05	0.000528	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—LCAT—atherosclerosis	5.08e-05	0.000528	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VWF—atherosclerosis	5.06e-05	0.000525	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CNR2—atherosclerosis	5.04e-05	0.000524	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—CXCL8—atherosclerosis	5.04e-05	0.000523	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MMP3—atherosclerosis	5.03e-05	0.000522	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—APOC3—atherosclerosis	5.03e-05	0.000522	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	5.02e-05	0.000521	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—LDLR—atherosclerosis	5e-05	0.000519	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOA4—atherosclerosis	4.99e-05	0.000518	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—F2—atherosclerosis	4.98e-05	0.000517	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PRKCG—atherosclerosis	4.97e-05	0.000516	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—AGT—atherosclerosis	4.92e-05	0.000511	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP7A1—atherosclerosis	4.9e-05	0.000509	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCL3—atherosclerosis	4.88e-05	0.000507	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—EDN1—atherosclerosis	4.78e-05	0.000497	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CG—atherosclerosis	4.76e-05	0.000495	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CCL5—atherosclerosis	4.75e-05	0.000493	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NCF1—atherosclerosis	4.67e-05	0.000485	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—F2—atherosclerosis	4.55e-05	0.000473	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KNG1—atherosclerosis	4.55e-05	0.000473	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP27A1—atherosclerosis	4.53e-05	0.00047	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AGTR1—atherosclerosis	4.52e-05	0.00047	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PRKCG—atherosclerosis	4.51e-05	0.000469	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VWF—atherosclerosis	4.49e-05	0.000467	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AGT—atherosclerosis	4.47e-05	0.000464	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APOC3—atherosclerosis	4.47e-05	0.000464	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—LDLR—atherosclerosis	4.44e-05	0.000461	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CCL2—atherosclerosis	4.44e-05	0.000461	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EDNRA—atherosclerosis	4.41e-05	0.000458	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCR2—atherosclerosis	4.41e-05	0.000458	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PLG—atherosclerosis	4.41e-05	0.000458	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CYBA—atherosclerosis	4.39e-05	0.000456	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AGT—atherosclerosis	4.37e-05	0.000454	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CG—atherosclerosis	4.35e-05	0.000452	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCL3—atherosclerosis	4.34e-05	0.00045	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GHRL—atherosclerosis	4.3e-05	0.000447	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PLAT—atherosclerosis	4.3e-05	0.000447	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PARP1—atherosclerosis	4.3e-05	0.000447	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALOX15—atherosclerosis	4.29e-05	0.000446	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	4.29e-05	0.000446	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOA2—atherosclerosis	4.29e-05	0.000446	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	4.29e-05	0.000446	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ABCG5—atherosclerosis	4.24e-05	0.00044	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SOCS3—atherosclerosis	4.17e-05	0.000433	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NCF1—atherosclerosis	4.15e-05	0.000431	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—F2—atherosclerosis	4.13e-05	0.000429	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—LPA—atherosclerosis	4.1e-05	0.000425	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—F2—atherosclerosis	4.04e-05	0.00042	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MMP3—atherosclerosis	4.03e-05	0.000419	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IGF2—atherosclerosis	4.01e-05	0.000417	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AGT—atherosclerosis	3.97e-05	0.000412	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—BGN—atherosclerosis	3.97e-05	0.000412	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CG—atherosclerosis	3.95e-05	0.000411	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOA5—atherosclerosis	3.93e-05	0.000408	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCR2—atherosclerosis	3.92e-05	0.000407	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EDNRA—atherosclerosis	3.92e-05	0.000407	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CYBA—atherosclerosis	3.9e-05	0.000405	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—APOB—atherosclerosis	3.9e-05	0.000405	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CG—atherosclerosis	3.87e-05	0.000402	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—CXCL8—atherosclerosis	3.86e-05	0.000401	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EDN1—atherosclerosis	3.83e-05	0.000398	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PARP1—atherosclerosis	3.82e-05	0.000397	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GHRL—atherosclerosis	3.82e-05	0.000397	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PLAT—atherosclerosis	3.82e-05	0.000397	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCL5—atherosclerosis	3.8e-05	0.000395	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	3.78e-05	0.000393	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KNG1—atherosclerosis	3.78e-05	0.000392	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AGTR1—atherosclerosis	3.75e-05	0.00039	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—LPL—atherosclerosis	3.72e-05	0.000386	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CCL2—atherosclerosis	3.68e-05	0.000382	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—F2—atherosclerosis	3.67e-05	0.000381	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PLG—atherosclerosis	3.66e-05	0.00038	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALOX5—atherosclerosis	3.65e-05	0.000379	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PRKCG—atherosclerosis	3.62e-05	0.000376	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SPP1—atherosclerosis	3.52e-05	0.000366	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CG—atherosclerosis	3.51e-05	0.000365	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CXCL8—atherosclerosis	3.51e-05	0.000364	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SOCS3—atherosclerosis	3.46e-05	0.00036	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KNG1—atherosclerosis	3.35e-05	0.000348	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MMP3—atherosclerosis	3.35e-05	0.000347	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AGTR1—atherosclerosis	3.33e-05	0.000346	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IGF2—atherosclerosis	3.33e-05	0.000346	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NAMPT—atherosclerosis	3.27e-05	0.00034	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CCL2—atherosclerosis	3.27e-05	0.00034	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PDGFB—atherosclerosis	3.26e-05	0.000339	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—LIPC—atherosclerosis	3.25e-05	0.000338	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PLG—atherosclerosis	3.25e-05	0.000337	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOC3—atherosclerosis	3.23e-05	0.000336	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—APOB—atherosclerosis	3.23e-05	0.000336	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—LDLR—atherosclerosis	3.21e-05	0.000334	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CXCL8—atherosclerosis	3.21e-05	0.000333	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AGT—atherosclerosis	3.18e-05	0.000331	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EDN1—atherosclerosis	3.18e-05	0.00033	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCL5—atherosclerosis	3.16e-05	0.000328	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CETP—atherosclerosis	3.14e-05	0.000326	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—LEP—atherosclerosis	3.12e-05	0.000324	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—APOE—atherosclerosis	3.12e-05	0.000324	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CAV1—atherosclerosis	3.09e-05	0.000321	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—LPL—atherosclerosis	3.09e-05	0.000321	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—APOA1—atherosclerosis	3.08e-05	0.00032	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SOCS3—atherosclerosis	3.08e-05	0.00032	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—SCARB1—atherosclerosis	3.01e-05	0.000312	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PRKCG—atherosclerosis	3e-05	0.000312	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ESR1—atherosclerosis	2.98e-05	0.000309	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MMP3—atherosclerosis	2.97e-05	0.000309	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IGF2—atherosclerosis	2.96e-05	0.000307	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—F2—atherosclerosis	2.94e-05	0.000305	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SPP1—atherosclerosis	2.92e-05	0.000304	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CXCL8—atherosclerosis	2.91e-05	0.000302	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APOB—atherosclerosis	2.87e-05	0.000298	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CXCL8—atherosclerosis	2.85e-05	0.000296	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—HMGCR—atherosclerosis	2.84e-05	0.000295	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EDN1—atherosclerosis	2.83e-05	0.000294	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CG—atherosclerosis	2.81e-05	0.000292	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCL5—atherosclerosis	2.8e-05	0.000291	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—LPL—atherosclerosis	2.74e-05	0.000285	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDGFB—atherosclerosis	2.71e-05	0.000281	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—MAPK3—atherosclerosis	2.69e-05	0.00028	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	2.67e-05	0.000277	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—INS—atherosclerosis	2.66e-05	0.000277	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AGT—atherosclerosis	2.64e-05	0.000274	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCL2—atherosclerosis	2.62e-05	0.000272	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	2.6e-05	0.00027	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—APOE—atherosclerosis	2.59e-05	0.000269	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—LEP—atherosclerosis	2.59e-05	0.000269	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	2.59e-05	0.000269	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IGF1—atherosclerosis	2.58e-05	0.000268	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CAV1—atherosclerosis	2.56e-05	0.000266	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—APOA1—atherosclerosis	2.56e-05	0.000266	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.53e-05	0.000263	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ESR1—atherosclerosis	2.47e-05	0.000257	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SERPINE1—atherosclerosis	2.45e-05	0.000254	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—F2—atherosclerosis	2.44e-05	0.000253	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	2.4e-05	0.00025	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AGT—atherosclerosis	2.35e-05	0.000244	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOS3—atherosclerosis	2.34e-05	0.000243	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CG—atherosclerosis	2.34e-05	0.000243	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APOE—atherosclerosis	2.3e-05	0.000239	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—LEP—atherosclerosis	2.3e-05	0.000239	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	2.28e-05	0.000237	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	2.27e-05	0.000236	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—MAPK3—atherosclerosis	2.24e-05	0.000232	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—INS—atherosclerosis	2.21e-05	0.00023	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	2.19e-05	0.000228	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCL2—atherosclerosis	2.18e-05	0.000226	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—HMOX1—atherosclerosis	2.17e-05	0.000225	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—F2—atherosclerosis	2.17e-05	0.000225	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IGF1—atherosclerosis	2.14e-05	0.000222	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOB—atherosclerosis	2.08e-05	0.000216	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	2.07e-05	0.000215	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CXCL8—atherosclerosis	2.07e-05	0.000215	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	2.03e-05	0.000211	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTM1—atherosclerosis	2.02e-05	0.00021	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—AKT1—atherosclerosis	2e-05	0.000208	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	1.99e-05	0.000206	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—LPL—atherosclerosis	1.99e-05	0.000206	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL6—atherosclerosis	1.97e-05	0.000205	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—INS—atherosclerosis	1.96e-05	0.000204	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	1.94e-05	0.000201	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GPX1—atherosclerosis	1.94e-05	0.000201	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	1.93e-05	0.000201	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	1.9e-05	0.000197	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CD36—atherosclerosis	1.89e-05	0.000196	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	1.87e-05	0.000195	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	1.85e-05	0.000193	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	1.82e-05	0.000189	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	1.82e-05	0.000189	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	1.8e-05	0.000187	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.79e-05	0.000186	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PPARA—atherosclerosis	1.75e-05	0.000182	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	1.72e-05	0.000179	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	1.72e-05	0.000179	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—AGT—atherosclerosis	1.7e-05	0.000176	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	1.68e-05	0.000175	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	1.67e-05	0.000173	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOE—atherosclerosis	1.66e-05	0.000173	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	1.66e-05	0.000173	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CAV1—atherosclerosis	1.65e-05	0.000171	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOA1—atherosclerosis	1.65e-05	0.000171	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	1.64e-05	0.00017	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	1.59e-05	0.000165	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	1.56e-05	0.000162	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	1.54e-05	0.00016	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.54e-05	0.00016	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	1.53e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.51e-05	0.000157	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.51e-05	0.000157	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.5e-05	0.000156	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	1.48e-05	0.000153	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	1.45e-05	0.000151	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PPARG—atherosclerosis	1.45e-05	0.000151	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—INS—atherosclerosis	1.42e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	1.4e-05	0.000145	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	1.38e-05	0.000144	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	1.38e-05	0.000144	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	1.37e-05	0.000142	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	1.34e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	1.34e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	1.32e-05	0.000137	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALB—atherosclerosis	1.3e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	1.28e-05	0.000133	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NOS3—atherosclerosis	1.25e-05	0.00013	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	1.24e-05	0.000129	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	1.23e-05	0.000128	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	1.17e-05	0.000122	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL6—atherosclerosis	1.16e-05	0.000121	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.14e-05	0.000118	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	1.14e-05	0.000118	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	1.07e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	9.66e-06	0.0001	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	8.91e-06	9.26e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	8.58e-06	8.91e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	7.92e-06	8.22e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—AKT1—atherosclerosis	5.73e-06	5.95e-05	CbGpPWpGaD
